- Home
- ORKA vs MESO Comparison
ORKA vs MESO Comparison
Compare ORKA & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORKA
- MESO
- Stock Information
- Founded
- ORKA 2004
- MESO 2004
- Country
- ORKA United States
- MESO Australia
- Employees
- ORKA N/A
- MESO N/A
- Industry
- ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ORKA Health Care
- MESO Health Care
- Exchange
- ORKA Nasdaq
- MESO Nasdaq
- Market Cap
- ORKA 866.2M
- MESO 861.6M
- IPO Year
- ORKA N/A
- MESO N/A
- Fundamental
- Price
- ORKA $25.47
- MESO $10.81
- Analyst Decision
- ORKA Strong Buy
- MESO Strong Buy
- Analyst Count
- ORKA 4
- MESO 4
- Target Price
- ORKA $41.33
- MESO $11.50
- AVG Volume (30 Days)
- ORKA 67.2K
- MESO 165.8K
- Earning Date
- ORKA 11-15-2024
- MESO 11-28-2024
- Dividend Yield
- ORKA N/A
- MESO N/A
- EPS Growth
- ORKA N/A
- MESO N/A
- EPS
- ORKA N/A
- MESO N/A
- Revenue
- ORKA N/A
- MESO $5,902,000.00
- Revenue This Year
- ORKA N/A
- MESO $66.05
- Revenue Next Year
- ORKA N/A
- MESO $348.27
- P/E Ratio
- ORKA N/A
- MESO N/A
- Revenue Growth
- ORKA N/A
- MESO N/A
- 52 Week Low
- ORKA $18.72
- MESO $1.61
- 52 Week High
- ORKA $53.88
- MESO $11.05
- Technical
- Relative Strength Index (RSI)
- ORKA N/A
- MESO 85.79
- Support Level
- ORKA N/A
- MESO $6.86
- Resistance Level
- ORKA N/A
- MESO $7.39
- Average True Range (ATR)
- ORKA 0.00
- MESO 0.47
- MACD
- ORKA 0.00
- MESO 0.40
- Stochastic Oscillator
- ORKA 0.00
- MESO 95.25
About ORKA Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics Inc is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. It is to offer patients suffering from chronic skin diseases like plaque psoriasis.
About MESO Mesoblast Limited
Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) and others.